Some Traders Are Very Bullish on Cytosorbents Corporation (CTSO) After Forming Bullish Wedge Up Chart Pattern

December 7, 2017 - By Kurt Siggers

Investors sentiment decreased to 0.73 in 2017 Q2. Its down 2.41, from 3.14 in 2017Q1. It dropped, as 4 investors sold Cytosorbents Corporation shares while 11 reduced holdings. 3 funds opened positions while 8 raised stakes. 1.87 million shares or 55.22% less from 4.19 million shares in 2017Q1 were reported.
Peak6 L P has invested 0% of its portfolio in Cytosorbents Corporation (NASDAQ:CTSO). 112,174 were accumulated by Blackrock Inc. State Street Corp stated it has 0% of its portfolio in Cytosorbents Corporation (NASDAQ:CTSO). 285 are owned by Jpmorgan Chase & Comm. The Wisconsin-based Skylands Cap Ltd Liability Company has invested 0.35% in Cytosorbents Corporation (NASDAQ:CTSO). Fortaleza Asset Mgmt Incorporated reported 12,875 shares stake. Aviance Capital owns 0% invested in Cytosorbents Corporation (NASDAQ:CTSO) for 1,580 shares. Glenmede Tru Co Na has 0% invested in Cytosorbents Corporation (NASDAQ:CTSO). 38,000 are held by Pnc Grp Inc. Salem Invest Counselors accumulated 13,000 shares. Vanguard Group owns 0% invested in Cytosorbents Corporation (NASDAQ:CTSO) for 452,056 shares. Morgan Stanley holds 2,507 shares or 0% of its portfolio. 36,840 are owned by Northern. Creative Planning, a Kansas-based fund reported 6,200 shares. Private Advisor Group Inc Ltd Liability Com reported 10,000 shares.

The stock of Cytosorbents Corporation (CTSO) formed an up wedge with $7.36 target or 9.00 % above today’s $6.75 share price. The 5 months wedge indicates low risk for the $193.67 million company. If the $7.36 price target is reached, the company will be worth $17.43M more.
Rising wedges, especially for downward breakouts are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 8% and 24%. The average rise is 28% and the decline is 14%. Wedges has high throwback and pullback rate: 73%, 63% and the percent of wedges meeting target is not more than 50%.

The stock increased 0.37% or $0.03 during the last trading session, reaching $6.75. About 69,790 shares traded. Cytosorbents Corporation (NASDAQ:CTSO) has declined 4.26% since December 8, 2016 and is downtrending. It has underperformed by 20.96% the S&P500.

Analysts await Cytosorbents Corporation (NASDAQ:CTSO) to report earnings on March, 2. They expect $-0.12 earnings per share, up 25.00 % or $0.04 from last year’s $-0.16 per share. After $-0.07 actual earnings per share reported by Cytosorbents Corporation for the previous quarter, Wall Street now forecasts 71.43 % negative EPS growth.

Cytosorbents Corporation (NASDAQ:CTSO) Ratings Coverage

Among 7 analysts covering CytoSorbents (NASDAQ:CTSO), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CytoSorbents had 12 analyst reports since October 29, 2015 according to SRatingsIntel. The stock has “Buy” rating by Maxim Group on Tuesday, August 8. The stock has “Buy” rating by Maxim Group on Wednesday, July 5. B. Riley & Co initiated it with “Buy” rating and $11.25 target in Friday, October 7 report. The firm has “Buy” rating by Aegis Capital given on Wednesday, October 26. The firm has “Buy” rating given on Tuesday, May 24 by Maxim Group. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, September 26. The firm has “Buy” rating given on Monday, July 17 by Maxim Group. Aegis Capital maintained Cytosorbents Corporation (NASDAQ:CTSO) rating on Tuesday, May 30. Aegis Capital has “Buy” rating and $900 target. WBB Securities upgraded Cytosorbents Corporation (NASDAQ:CTSO) rating on Thursday, October 29. WBB Securities has “Buy” rating and $13.0 target.

More notable recent Cytosorbents Corporation (NASDAQ:CTSO) news were published by: Seekingalpha.com which released: “CytoSorbents’ (CTSO) CEO Dr. Phillip Chan on Q2 2017 Results – Earnings Call …” on August 08, 2017, also Seekingalpha.com with their article: “Cytosorbents Corp (CTSO) CEO Phillip Chan Q3 2017 Results – Earnings Call …” published on November 10, 2017, Prnewswire.com published: “Dr. Eric R. Mortensen, MD, Ph.D., Clinical Trial Veteran, Joins CytoSorbents …” on May 30, 2017. More interesting news about Cytosorbents Corporation (NASDAQ:CTSO) were released by: Seekingalpha.com and their article: “Cytosorbents: A Razor & Razor Blade Story” published on June 28, 2017 as well as Prnewswire.com‘s news article titled: “CytoSorbents to Report Q2 2017 Operating and Financial Results” with publication date: August 01, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.